Wesbanco Bank Inc. Makes New $674,000 Investment in Abivax SA Sponsored ADR $ABVX

Wesbanco Bank Inc. bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,000 shares of the company’s stock, valued at approximately $674,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. TCG Crossover Management LLC grew its position in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after buying an additional 1,055,000 shares during the period. UBS Group AG grew its position in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Abivax in the third quarter valued at approximately $263,698,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Abivax in the third quarter valued at approximately $132,800,000. Finally, Octagon Capital Advisors LP grew its position in shares of Abivax by 3.0% in the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after purchasing an additional 37,000 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of ABVX opened at $122.74 on Monday. The company has a market capitalization of $9.73 billion, a price-to-earnings ratio of -22.86 and a beta of 0.84. The company’s 50 day simple moving average is $116.69 and its 200 day simple moving average is $117.23. Abivax SA Sponsored ADR has a 1 year low of $5.59 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The company had revenue of $0.52 million for the quarter. Equities analysts expect that Abivax SA Sponsored ADR will post -3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

ABVX has been the topic of several research reports. Jefferies Financial Group initiated coverage on shares of Abivax in a research report on Monday, March 16th. They issued a “buy” rating and a $160.00 price target on the stock. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. Finally, Barclays increased their price target on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Abivax currently has a consensus rating of “Moderate Buy” and an average target price of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.